Conditions: Schizophrenia and Disorders With Psychotic Features
Keywords: Ziprasidone metabolic syndrome risk factors schizophrenia psychotic disorders.
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 172
Healthy volunteers: no

Brief summary:
The purpose of this study is to explore the impact of ziprasidone on the distribution of metabolic syndrome risk factors in a population of patients presenting with glucose intolerance, dyslipidemia and/or elevated waist circumference associated with their current antipsychotic medication.

Detailed description:
The trial was terminated prematurely on May 24, 2012, due to changes in organizational strategy and resources. The decision to terminate the trial was not based on any safety or efficacy concerns.

Arms:
arm 1: None

Interventions: intervention 1: Ziprasidone HCL (oral)
Intervention descriptions: intervention 1: Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40 to 160 mg total daily dose) for up to 1 year.

Protocol document: